GeneLeap Announces Novel GalNAc Synthesis and Evaluation in Mice as Antisense Oligonucleotide Conjugates at ACS 2021

BOSTON, April 25, 2021 /PRNewswire/ -- GeneLeap Biotech, a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an e-poster entitled 'Design and synthesis of novel GalNAc linker moieties, conjugation to antisense oligonucleotides and...

from PR Newswire: https://ift.tt/3dPkoRr